ADURO BIOTECH, INC. (39)

Browse by Contract Category

Contracts

Sublease between the Registrant and Wireless Advocates LLC dated May 24, 2021 (Filed With SEC on August 12, 2021)
Form of Inducement Stock Option Agreement (Filed With SEC on April 7, 2021)
Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on April 7, 2021)
Form of Consulting Agreement (Filed With SEC on October 7, 2020)
Form of Indemnification Agreement (Filed With SEC on October 7, 2020)
Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated August 17, 2020, by and among Aduro Biotech, Inc., Aspire Merger Sub, Inc. and Chinook Therapeutics U.S.,... (Filed With SEC on August 18, 2020)
License Agreement, dated December 16, 2019, by and between Chinook Therapeutics U.S., Inc. and AbbVie Ireland Unlimited Company (Filed With SEC on July 22, 2020)
Sublease between the Registrant and Perfect Day, Inc., dated August 25, 2020 (Filed With SEC on November 5, 2020)
Contingent Value Rights Agreement, dated October 2, 2020, by and between Aduro Biotech, Inc. and Computershare Trust Company, N.A (Filed With SEC on November 5, 2020)
Form of Separation Agreement (Standard) (Filed With SEC on October 7, 2020)
Form of Separation Agreement (Stephen T. Isaacs) (Filed With SEC on October 7, 2020)
Form of Employment Agreement (US) (Filed With SEC on October 7, 2020)
Form of Employment Agreement (Canada) (Filed With SEC on October 7, 2020)
Note Termination Agreement, dated August 17, 2020, by and among Aduro Biotech, Inc., Chinook Therapeutics U.S., Inc. and certain investors named therein (Filed With SEC on August 18, 2020)
Amended and Restated Executive Employment Agreement by and between the Company and Stephen T. Isaacs, dated July 2, 2020 (Filed With SEC on July 2, 2020)
Amendment to the Aduro Biotech, Inc. Amended and Restated Severance Plan and Summary Plan Description (Filed With SEC on July 2, 2020)
Letter Agreement by and between the Company and Blaine Templeman, dated June 29, 2020 (Filed With SEC on July 2, 2020)
Form of Support Agreement by and between Chinook Therapeutics U.S., Inc. and certain stockholders of Aduro Biotech, Inc (Filed With SEC on June 2, 2020)
Consulting Agreement, dated as of June 1, 2020, by and between Aduro Biotech, Inc. and Andrea van Elsas, Ph.D (Filed With SEC on June 2, 2020)
Form of CVR Agreement (Filed With SEC on June 2, 2020)
Form of Lock-Up Agreement (Filed With SEC on June 2, 2020)
Note Purchase Agreement, dated as of June 1, 2020, by and among Chinook Therapeutics U.S., Inc. and certain investors named therein (Filed With SEC on June 2, 2020)
Form of Support Agreement by and between Aduro Biotech, Inc. and certain stockholders of Chinook Therapeutics U.S., Inc (Filed With SEC on June 2, 2020)
Agreement and Plan of Merger and Reorganization, dated June 1, 2020, by and among Aduro Biotech, Inc., Aspire Merger Sub, Inc. and Chinook Therapeutics U.S., Inc (Filed With SEC on June 2, 2020)
Form of Convertible Promissory Note (Filed With SEC on June 2, 2020)
Termination Agreement between Andrea van Elsas and Aduro Biotech, Inc. dated April 10, 2020 (Filed With SEC on May 4, 2020)
Amendment No. 3 to Exclusive License Agreement between Aduro Biotech, Inc. and the Memorial Sloan Kettering Cancer Center, dated March 30, 2020 (Filed With SEC on May 4, 2020)
Retention Bonus Agreement dated January 9, 2020, between the Company and Dimitry Nuyten (Filed With SEC on March 9, 2020)
Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 9, 2020)
Retention Bonus Agreement dated January 9, 2020, between the Company and Blaine Templeman (Filed With SEC on March 9, 2020)
Retention Bonus Agreement dated January 9, 2020, between the Company and Celeste Ferber (Filed With SEC on March 9, 2020)
Retention Bonus Agreement dated January 10, 2020, between the Company and Stephen T. Isaacs (Filed With SEC on March 9, 2020)
Amendment No. 2 to Executive Employment Agreement dated January 13, 2020, between the Company and Stephen T. Isaacs (Filed With SEC on March 9, 2020)
Consulting Agreement dated January 22, 2020, between the Company and Danforth Advisors, LLC (Filed With SEC on January 23, 2020)
Offer of Employment Letter of Chief Medical Officer (Filed With SEC on August 1, 2019)
Offer of Employment Letter of Interim Chief Financial Officer (Filed With SEC on August 1, 2019)
Aduro Biotech, Inc. Non-Employee Director Compensation Policy (Filed With SEC on May 7, 2019)
Research Collaboration and Exclusive License Agreement between Aduro Biotech, Inc. and Eli Lilly and Company, dated December 18, 2018 (Filed With SEC on February 27, 2019)
Amendment No. 1 to Sales Agreement between Aduro Biotech, Inc. and Cowen and Company, LLC, dated February 27, 2019 (Filed With SEC on February 27, 2019)